Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Cell Therapeutics takes no chances

Most companies only bite the bullet and downsize when disaster is imminent. But after raising $32 million from private investors, Cell Therapeutics Inc. is proactively restructuring as it prepares to go into pivotal clinical trials.

The company

Read the full 368 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers